PresentationRobert SassoonWater Tower Research LLC Hello, everybody. I'm Robert Sassoon. I cover health care at Water Tower Research. Today, I have the pleasure of being joined in this fireside chat by Anixa Biosciences' Chairman and CEO, Dr. Amit Kumar. Anixa is a clinical stage biotech company, which develops a novel type of CAR-T cell therapy for the treatment of termly ill ovarian cancer patients and separately, a vaccine for the treatment and prevention of breast cancer. Anixa has also additional pred ...

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]

Group 1 - Water Tower Research (WTR) experienced a technical issue during a recent Fireside Chat with Anixa Biosciences, leading to an interruption in the live broadcast [1] - The session was fully recorded and is now available for on-demand viewing [1] - WTR's CEO, Shawn Severson, apologized for the inconvenience and stated that the technical issue has been resolved to ensure future sessions proceed without interruption [1] Group 2 - The Fireside Chat Series by Water Tower Research aims to connect investors with management teams from innovative public and private companies through open-access discussions [1] - Water Tower Research focuses on modernizing investor engagement through research-driven communications, providing equal access to high-quality company research for all investors [3] - The company distributes its research and investor content across various platforms, including traditional research aggregators and social media, to enhance investor relations [3]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which targets the -lactalbumin protein, a promising approach for immunoprevention strategies against breast cancer [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a strong emphasis on developing next-generation preventive immunotherapies [2][5] - The company has a collaboration with Cleveland Clinic for the development of its breast cancer vaccine, which is part of a broader portfolio that includes ovarian cancer immunotherapy [5] Patent and Intellectual Property - The U.S. Patent Number 12,472,205 will be issued on November 18, 2025, extending the intellectual property protection for Anixa's breast cancer vaccine technology into the mid-2040s [1][2] - This patent reinforces the company's commitment to addressing breast cancer, which is projected to affect nearly 300,000 women in the U.S. by 2026 [1][3] Market Need - Breast cancer remains the most commonly diagnosed cancer among women globally, with over 297,000 new cases expected in the U.S. in 2025 and approximately 43,000 deaths anticipated [3] - There is currently no FDA-approved vaccine for breast cancer prevention, highlighting a significant unmet need in preventive oncology [3] Vaccine Mechanism - Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate cells expressing -lactalbumin while sparing normal tissue, potentially minimizing off-target effects [4]

Accessibility StatementSkip Navigation SAN JOSE, Calif., Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, November 11, 2025, at 11:00am PT. The Fireside Chat wil be hosted by Robert Sassoon, Managing Director – Healthcare at Wat ...

Core Insights - Anixa Biosciences has executed a data transfer agreement with Cleveland Clinic, marking a significant step in transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development [1][2][4] Group 1: Clinical Development - Enrollment for the Phase 1 trial has been completed, showing encouraging immune response data, leading Anixa to advance the vaccine into a Phase 2 clinical trial [2] - The IND, currently sponsored by Cleveland Clinic, is in the process of being transferred to Anixa, allowing the company to assume full sponsorship [2][4] Group 2: Vaccine Technology - The breast cancer vaccine targets -lactalbumin, a protein typically expressed in breast tissue during lactation, which re-emerges in various forms of breast cancer [3] - By establishing an immune response against -lactalbumin-expressing cells, the vaccine may provide both therapeutic and preventive benefits for patients with tumors expressing this protein [3] Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, as well as additional vaccines targeting other cancers, developed in collaboration with Cleveland Clinic [4]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology in China, extending intellectual property protection until 2040, which enhances its global patent portfolio and supports future commercialization strategies [1][3]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [5]. Vaccine Technology - The breast cancer vaccine targets human-lactalbumin, a protein linked to lactation that is abnormally expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation without damaging normal tissue [2][4]. Clinical Development - A Phase 1 clinical trial for the breast cancer vaccine has been completed, with full results to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [4]. Intellectual Property Strategy - The newly issued patent reinforces Anixa's intellectual property strategy, allowing for broader international development and commercialization opportunities in regions with high breast cancer incidence [3][4].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: ANIXA BIOSCIENCES INC - ANIXA BIOSCIENCES INC currently holds a Momentum Style Score of B, indicating a positive outlook based on price changes and earnings estimate revisions [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Price Performance - Over the past week, ANIX shares have increased by 32.42%, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.34% [5] - In a longer timeframe, ANIX shares have risen by 30.56% over the past month, compared to the industry's 6.3% performance [5] - Over the last three months, ANIX shares have gained 30.56%, and over the past year, they have increased by 47.16%, significantly outperforming the S&P 500, which moved 6.17% and 14.81% respectively [6] Trading Volume - ANIX's average 20-day trading volume is 281,328 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for ANIX has increased, while none have decreased, leading to a consensus estimate rise from -$0.38 to -$0.35 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating a positive trend in earnings expectations [9] Conclusion - Given the strong price performance, positive earnings outlook, and favorable momentum indicators, ANIXA BIOSCIENCES INC is positioned as a promising investment opportunity [11]

Core Insights - Anixa Biosciences has completed the final patient visit in its breast cancer vaccine clinical trial, marking a significant milestone in the first-in-human evaluation of the vaccine [1][3] - The vaccine aims to stimulate the immune system to recognize and target breast cancer before recurrence or development [2] - Preliminary results indicate that over 70% of participants demonstrated immune responses, suggesting the vaccine is well tolerated [4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer in partnership with Cleveland Clinic, which has exclusive licensing rights to these technologies [5] - Anixa's business model involves partnering with leading research institutions to explore emerging technologies for cancer treatment [5] Clinical Trial Details - The Phase 1 trial included 35 women across three cohorts: 26 in the TNBC group, 4 in the Prevention group, and 5 in the Pembrolizumab group [2][6] - Comprehensive data analysis will follow the completion of patient visits, with results to be submitted to the Department of Defense and the FDA [3] - Full clinical results are scheduled to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [3]

Core Insights - Anixa Biosciences has announced the final results of its Phase 1 clinical trial for a breast cancer vaccine, which will be presented at the 2025 San Antonio Breast Cancer Symposium [1][2][3] - The trial, funded by the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer [2][3] - The results are expected to inform discussions with the FDA and advance plans for Phase 2 development [1][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine technologies target "retired" proteins expressed in certain cancers, including breast and ovarian cancer, developed at Cleveland Clinic and exclusively licensed to Anixa [4] - Anixa's business model involves partnerships with leading research institutions to explore emerging technologies for further development and commercialization [4]